The artificial intelligence-based assay relies on images from an H&E-stained biopsy slide and a machine-learning model to ...

The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

NEW YORK – Aiforia Technologies, a developer of technologies for pathology using artificial intelligence, said on Tuesday that it has received CE-IVD marking for a breast cancer grading test that the ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

NEW YORK — Sysmex America said Wednesday that it has received licensing from Health Canada for its CN-3000 and CN-6000 automated blood coagulation analyzers. The CN-3000 and CN-6000 are designed for ...

NEW YORK – Oncology diagnostics firm MetasTx said Wednesday that it secured a $500,000 Small Business Innovation Research (SBIR) grant from the National Cancer Institute to support development of a ...

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...